Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

✍ Scribed by Pier Luigi Zinzani, Nuriet K Khuageva, Huaqing Wang, Bernardo Garicochea, Jan Walewski, Achiel Van Hoof, Pierre Soubeyran, Dolores Caballero, Rena Buckstein, Dixie-Lee Esseltine, Panteli Theocharous, Christopher Enny, Eugene Zhu, Yusri A Elsayed, Bertrand Coiffier

• Book ID: 119913657
• Publisher: BioMed Central
• Year: 2012
• Tongue: English
• Weight: 253 KB
• Volume: 5
• Category: Article
• ISSN: 1756-8722
• DOI: 10.1186/1756-8722-5-67